Inactive Instrument

Highlights Qiagen NV Nasdaq

Equities

NL0000240000

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use	Apr. 24	CI
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	Apr. 03	CI
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland	Mar. 27	CI
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System	Mar. 25	CI
Qiagen Teams Up With Physicians Association for Tuberculosis Screening Program	Mar. 18	MT
Volta Labs Partners with OEM by QIAGEN to Unlock Potential of NGS Sample Prep	Feb. 08	CI
QIAGEN : In line Q4; routine business prospects remain intact	Feb. 07
Dpa-AFX Overview: COMPANIES from 07.02.2024 - 15:15	Feb. 07	DP
Qiagen Q4 Adjusted Earnings, Sales Rise; 2024 Outlook Issued, Shares Slump	Feb. 06	MT
Qiagen N.V. Provides Earnings Guidance for Year 2024	Feb. 06	CI
Qiagen N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 05	CI
Qiagen N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 05	CI
Reverse Split: 24.25 of 25	Jan. 29	FA
Capital return instalment	Jan. 29	FA
Qiagen, Pennsylvania State University to Establish Microbiome Research, Education Facility	Jan. 25	MT
QIAGEN Announces Collaboration with Penn State University in United States to Create Shared Research and Education Facility for Fast-Developing Microbiome Sciences	Jan. 25	CI
Qiagen Sets Terms for Synthetic Share Repurchase of Up to $300 Million	Jan. 19	MT
Dpa-AFX Overview: COMPANIES from 19.01.2024 - 15:15	Jan. 19	DP
Qiagen Seeks M&A	Jan. 08	CI
Qiagen Plans to Return Up to $300 Million to Shareholders in Synthetic Share Repurchase	Jan. 08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

QIAGEN : In line Q4; routine business prospects remain intact

February 07, 2024 at 10:30 am EST